CD47 as a promising therapeutic target in oncology

Hai Zhao; Shuangshuang Song; Junwei Ma; Zhiyong Yan; Hongwei Xie; Ying Feng; Shusheng Che

doi:10.3389/fimmu.2022.757480

CD47 as a promising therapeutic target in oncology

Front Immunol. 2022 Aug 22:13:757480. doi: 10.3389/fimmu.2022.757480. eCollection 2022.

Authors

Hai Zhao¹, Shuangshuang Song², Junwei Ma¹, Zhiyong Yan¹, Hongwei Xie¹, Ying Feng³, Shusheng Che¹

Affiliations

¹ Department of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, China.
² Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao, China.
³ Department of Emergency, the Affiliated Hospital of Qingdao University, Qingdao, China.

Abstract

CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.

Keywords: CD47; SIRPα; atherosclerosis; cancer immunotherapy; immune modulation; immunotherapies; neurological disorders.

Publication types

Review

MeSH terms

CD47 Antigen*
Humans
Immunotherapy* / methods
Macrophages
Neoplasms* / immunology
Neoplasms* / therapy
Phagocytosis

Substances

CD47 Antigen
CD47 protein, human